Four patients in Denmark will receive compensation after developing serious eye conditions from the weight-loss and diabetes ...

More than 40 people sought reimbursement after they said they had developed a serious eye condition as a result of using the ...

The authority said it has received 43 claims from patients who believe they developed the condition known as NAION after ...

Four Danish patients who experienced vision loss after using Novo Nordisk's Wegovy and Ozempic were awarded compensation ...

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk’s popular weight-loss and diabetes drugs ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access ...